Discussing Pivotal Progress in Breast Cancer in Dallas

June 19, 2019

We traveled to Dallas, Texas, for a State of the Science Summit™ on Breast Cancer, where faculty relayed the prognostic value of genomic assays in breast cancer and the scope of established and ensuing treatment approaches for those with early-stage and advanced disease.

We recently traveled to Dallas, Texas, for a State of the Science Summit™ on Breast Cancer. At the meeting, faculty from Baylor Scott and White Health System and The University of Texas MD Anderson Cancer Center relayed the prognostic value of genomic assays in breast cancer and the scope of established and ensuing treatment approaches for those with early-stage and advanced disease.